{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-018315","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2022-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.193011+00:00","generated_at":"2026-06-23T11:16:44.024579+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dyne doses first patient in DYNE-251 DMD trial, initiates DYNE-101 DM1 trial, defers FSHD IND","bullets":["First patient dosed in Phase 1/2 DELIVER trial of DYNE-251 for DMD exon 51 skipping; registrational trial targeting ~46 patients.","Initiated Phase 1/2 ACHIEVE trial for DYNE-101 in DM1; first patient expected in September 2022; target ~64 adult patients.","Deferring IND submission for DYNE-301 (FSHD) originally planned for H2 2022; update expected in 2023.","Cash runway extended through 2024 due to FSHD program deferral, based on existing cash and equivalents."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-018315","json":"https://secwatch.observer/filing/0000950170-22-018315.json","markdown":"https://secwatch.observer/filing/0000950170-22-018315.md","text":"https://secwatch.observer/filing/0000950170-22-018315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022018315/0000950170-22-018315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000095017022018315/dyn-20220906.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T11:16:44.024579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}